{"id":"NCT01934140","sponsor":"Pfizer","briefTitle":"Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination","officialTitle":"A PHASE IIIB, OPEN, MULTI-CENTER STUDY TO EVALUATE THE LONG-TERM ANTIBODY PERSISTENCE AT 6, 7, 8, 9 AND 10 YEARS AFTER THE ADMINISTRATION OF ONE DOSE OF MENINGOCOCCAL CONJUGATE VACCINE MENACWY-TT VERSUS ONE DOSE OF MENINGOCOCCAL POLYSACCHARIDE VACCINE MENCEVAX(REGISTERED) ACWY, AND TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER PRIMARY VACCINATION OF 11-55 YEAR OLD SUBJECTS WITH MENACWY-TT OR MENCEVAX (REGISTERED) ACWY.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2018-02","completion":"2018-08","firstPosted":"2013-09-04","resultsPosted":"2019-08-28","lastUpdate":"2019-08-28"},"enrollment":311,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal vaccine GSK134612","otherNames":[]}],"arms":[{"label":"ACWY-TT group","type":"EXPERIMENTAL"},{"label":"MenPS group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the long-term antibody persistence from 6, 7, 8, 9 to 10 years post-administration of MenACWY-TT conjugate vaccine as compared to Mencevax ACWY when given to healthy subjects 11 to 55 years of age. In addition, the safety and immunogenicity of a booster dose of MenACWY-TT vaccine administered to all eligible subjects 10 years after the primary vaccination will be evaluated.\n\nAll Filipino subjects who received the primary vaccination in the primary vaccination study 107386 (NCT00356369) will be invited to enrol in the long-term follow up and booster phase. No new subjects will be enrolled.","primaryOutcome":{"measure":"Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers Greater Than or Equal to (>=) 1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination","timeFrame":"After 6 years of primary vaccination","effectByArm":[],"pValues":[]},"eligibility":{"minAge":"17 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":2,"countries":["Philippines"]},"refs":{"pmids":["32552685"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=MENACWY-TT-099&StudyName=A+Phase+Iiib%2C+Open%2C+Multi-center+Study+To+Evaluate+The+Long-term+Antibody+Persistence+At+6%2C+7%2C+8%2C+9+And+10+Years+After+The+Administration+Of+One+Dose+Of+Meningococcal+Conjugate+Vaccine+Menacwy-tt+Versus+One+Dose+Of+Meningococcal+Polysaccharide+Vaccine+Mencevax%28registered%29+Acwy%2C+And+To+Evaluate+The+Safety+And+Immunogenicity+Of+A+Booster+Dose+Of+Menacwy-tt+Vaccine+Administered+10+Years+After+Primary+Vaccination+Of+11-55+Year+Old+Subjects+With+Menacwy-tt+Or+Mencevax+%28registered%29+Acwy."]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":235},"commonTop":["Injection site pain (pain at injection site)","Fatigue","Headache","Injection site erythema (redness)","Injection site swelling (swelling)"]}}